Prothrombin Complex Concentrate for Emergent Reversal of Intracranial Hemorrhage in Patients with Ventricular Assist Devices
Tóm tắt
Intracranial hemorrhage (ICH) is a devastating complication for patients with ventricular assist devices (VADs). The safety of emergent anticoagulation reversal with four-factor prothrombin complex concentrate (PCC) and optimal timing of anticoagulation resumption are not clear. In addition, lactate dehydrogenase (LDH) is used as a biomarker for thromboembolic risk, but its utility in guiding anticoagulation management after reversal with PCC has not be described. We retrospectively reviewed a consecutive series of patients with VADs presenting with ICH between 2014 and 2020 who received four-factor PCC for rapid anticoagulation reversal. We collected the timing of PCC administration, timing of resumption of anticoagulation, survival, occurrence of thromboembolic events, and LDH levels throughout hospitalization. We identified 16 ICH events in 14 patients with VADs treated with rapid anticoagulation reversal using four-factor PCC (11 intraparenchymal, 4 subdural, 1 subarachnoid hemorrhage). PCC was administered at a mean of 3.3 ± 0.3 h after imaging diagnosis of ICH. Overall mortality was 63%. Survivors had higher presenting Glasgow Coma Scale (median 15, interquartile range [IQR] 15–15 versus 14, IQR 8–14.7, P = 0.041). In all six instances where the patient survived, anticoagulation was resumed on average 9.16 ± 1.62 days after reversal. There were no thromboembolic events prior to resumption of anticoagulation. Three events occurred after anticoagulation resumption and within 3 months of reversal: VAD thrombosis in a patient with thrombosis at the time of reversal, ischemic stroke, and readmission for elevated LDH in the setting of subtherapeutic international normalized ratio. Our limited series found no thromboembolic complications immediately following anticoagulation reversal with PCC prior to resumption of anticoagulation. LDH trends may be useful to monitor thromboembolic risk after reversal.
Tài liệu tham khảo
Colombo PC, Mehra MR, Goldstein DJ, Estep JD, Salerno C, Jorde UP, et al. Comprehensive analysis of stroke in the long-term cohort of the MOMENTUM 3 study. Circulation. 2019;139:155–68.
Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in HeartMate II and HeartWare left ventricular assist devices: a systematic review. Neurocrit Care. 2017;27:17–25.
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376:451–60.
Milano CA, Rogers JG, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. HVAD: the ENDURANCE supplemental trial. JACC Heart Fail. 2018;6:792–802.
Florisson DS, Conte SM, De Bono JA, Newcomb AE. Do patients with the centrifugal flow HeartMate 3 or HeartWare left ventricular assist device have better outcomes compared to those with axial flow HeartMate II? Interact Cardiovasc Thorac Surg. 2019;29:844–51.
Tsiouris A, Heliopoulos I, Mikroulis D, Mitsias PD. Factors defining occurrence of ischemic and hemorrhagic strokes during continuous flow left ventricular assist device support. Gen Thorac Cardiovasc Surg. 2020;68:319–27.
Shahreyar M, Bob-Manuel T, Khouzam RN, Bashir MW, Sulaiman S, Akinseye O, et al. Trends, predictors and outcomes of ischemic stroke and intracranial hemorrhage in patients with a left ventricular assist device. Ann Transl Med. 2018;6:5.
Rossi M, Serraino GF, Jiritano F, Renzulli A. What is the optimal anticoagulation in patients with a left ventricular assist device? Interact Cardiovasc Thorac Surg. 2012;15:733–40.
Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.
Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37:151–5.
Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–36.
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157–87.
Wong JK, Chen PC, Falvey J, Melvin AL, Lidder AK, Lowenstein LM, et al. Anticoagulation reversal strategies for left ventricular assist device patients presenting with acute intracranial hemorrhage. ASAIO J. 2016;62:552–7.
Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.
Steiner T, Poli S, Griebe M, Hüsing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566–73.
Rimsans J, Levesque A, Lyons E, Sylvester K, Givertz MM, Mehra MR, et al. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. J Thromb Thrombolysis. 2018;46:180–5.
Cho SM, Moazami N, Katz S, Starling R, Frontera JA. Reversal and resumption of antithrombotic therapy in LVAD-associated intracranial hemorrhage. Ann Thorac Surg. 2019;108:52–8.
Jennings DL, Rimsans J, Connors JM. Prothrombin complex concentrate for warfarin reversal in patients with continuous-flow left ventricular assist devices: a narrative review. ASAIO J. 2020;66:482–8.
Sood V, Alam O, Tchantchaleishvili V, Pagani FD, Aaronson KD, Haft J, et al. Correlation of pre-explant lactate dehydrogenase concentrations and findings during post-explant pump analysis of the HeartMate II left ventricular assist device. Ann Thorac Surg. 2017;103:1207–13.
Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.
Hurst TE, Xanthopoulos A, Ehrlinger J, Rajeswaran J, Pande A, Thuita L, et al. Dynamic prediction of left ventricular assist device pump thrombosis based on lactate dehydrogenase trends. ESC Heart Fail. 2019;6:1005–14.
Shah P, Mehta VM, Cowger JA, Aaronson KD, Pagani FD. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant. 2014;33:102–4.
Lai GY, Devlin PJ, Kesavabhotla K, Rich JD, Pham DT, Potts MB, et al. Management and outcome of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2019;132:1133–9.
Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27:1304–5.
Won SY, Zagorcic A, Dubinski D, Quick-Weller J, Herrmann E, Seifert V, et al. Excellent accuracy of ABC/2 volume formula compared to computer-assisted volumetric analysis of subdural hematomas. PLoS ONE. 2018;13:e0199809.
Carroll AH, Ramirez MP, Dowlati E, Mueller KB, Borazjani A, Chang JJ, et al. Management of intracranial hemorrhage in patients with a left ventricular assist device: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30:105501.
Wilson TJ, Stetler WR Jr, Al-Holou WN, Sullivan SE, Fletcher JJ. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118:1063–8.
Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, et al. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transplant. 2016;35:1003–9.
Brekelmans MPA, Abdoellakhan RA, Scheres LJJ, Biedermann JS, Hutten BA, Meijer K, et al. Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate. Res Pract Thromb Haemost. 2018;2:77–84.
Santos CD, Matos NL, Asleh R, Dawit S, Rabinstein AA, O’Carroll CB, et al. The dilemma of resuming antithrombotic therapy after intracranial hemorrhage in patients with left ventricular assist devices. Neurocrit Care. 2020;32:822–7.